These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7791104)

  • 1. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
    Deleu D; Sarre S; Ebinger G; Michotte Y
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1323-31. PubMed ID: 7791104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle.
    Deleu D; Sarre S; Ebinger G; Michotte Y
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Dec; 348(6):576-81. PubMed ID: 8133901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
    Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
    Rose S; Jenner P; Marsden CD
    J Pharm Pharmacol; 1991 May; 43(5):325-30. PubMed ID: 1680174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
    Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
    Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous monitoring of levodopa, dopamine and their metabolites in skeletal muscle and subcutaneous tissue in different pharmacological conditions using microdialysis.
    Deleu D; Sarre S; Ebinger G; Michotte Y
    J Pharm Biomed Anal; 1993 Jul; 11(7):577-85. PubMed ID: 8399532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic administration does not alter the accumulation of L-dopa into muscle.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1994 Mar; 9(2):167-72. PubMed ID: 8196677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
    Ahtila S; Kaakkola S; Gordin A; Korpela K; Heinävaara S; Karlsson M; Wikberg T; Tuomainen P; Männistö PT
    Clin Neuropharmacol; 1995 Feb; 18(1):46-57. PubMed ID: 8665534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
    Bugamelli F; Marcheselli C; Barba E; Raggi MA
    J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
    Kaakkola S; Wurtman RJ
    J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
    Brusa L; Pierantozzi M; Bassi A; Fedele E; Lunardi G; Giacomini P; Stanzione P
    Neurol Sci; 2004 Jun; 25(2):53-6. PubMed ID: 15221622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
    Smith LA; Gordin A; Jenner P; Marsden CD
    Mov Disord; 1997 Nov; 12(6):935-45. PubMed ID: 9399218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
    Keränen T; Gordin A; Harjola VP; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Seppälä L; Wikberg T
    Clin Neuropharmacol; 1993 Apr; 16(2):145-56. PubMed ID: 8477410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative microdialysis for studying the in vivo L-DOPA kinetics in blood and skeletal muscle of the dog.
    Sarre S; Deleu D; Van Belle K; Ebinger G; Michotte Y
    Pharm Res; 1995 May; 12(5):746-50. PubMed ID: 7479562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
    Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeic acid improves the bioavailability of L-dopa in rabbit plasma.
    Wang LH; Hsu KY; Uang YS; Hsu FL; Yang LM; Lin SJ
    Phytother Res; 2010 Jun; 24(6):852-8. PubMed ID: 19941381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous in vivo microdialysis in plasma and skeletal muscle: a study of the pharmacokinetic properties of levodopa by noncompartmental analysis.
    Deleu D; Sarre S; Michotte Y; Ebinger G
    J Pharm Sci; 1994 Jan; 83(1):25-8. PubMed ID: 8138904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
    Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.